In situ pharmacoproteomics for the prediction of efficacy and side effects

2015 Fiscal Year Final Research Report

• Project/Area Number: 26640098
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Tumor diagnostics
• Research Institution: National Institutes of Biomedical Innovation, Health and Nutrition
• Principal Investigator: ADACHI JUN 国立研究開発法人医薬基盤・健康・栄養研究所, プロテオームリサーチプロジェクト, 研究員 (20437255)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: キナーゼ阻害剤 / プロテオミクス

Outline of Final Research Achievements

We developed a 3D-Pharmacoproteomics (3D-PPx）method to identify targets of ATP-competitive kinase inhibitors at the various scale of concentrations and inhibition time points. We applied 3D-PPx to find targets of erlotinib, an EGFR inhibitor used as an anti-cancer drug. We confirmed that 3D-PPx can detect the effect of EGFR mutation using erlotinib-resistant NSCLC cells which express wild-type EGFR and erlotinib-sensitive NSCLC cells which express mutant EGFR. Furthermore, several target candidates of erlotinib were identified using 3D-PPx.

Free Research Field

プロテオミクス